A practical guide to the handling and administration of talimogene laherparepvec in Europe.

Details

Ressource 1Download: 28814886_BIB_97554E7633A7.pdf (1603.99 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_97554E7633A7
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
A practical guide to the handling and administration of talimogene laherparepvec in Europe.
Journal
OncoTargets and therapy
Author(s)
Harrington K.J., Michielin O., Malvehy J., Pezzani Grüter I., Grove L., Frauchiger A.L., Dummer R.
ISSN
1178-6930 (Print)
ISSN-L
1178-6930
Publication state
Published
Issued date
2017
Peer-reviewed
Oui
Volume
10
Pages
3867-3880
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease. Talimogene laherparepvec is a genetically modified viral therapy, and its handling needs special attention due to its deep freeze, cold-chain requirements, its potential for viral shedding, and its administration by direct intralesional injection. This review provides a practical overview of handling, storage, and administration procedures for this agent in Europe. Talimogene laherparepvec vials should be transported/stored frozen at a temperature of -90°C to -70°C, and once thawed, vials must not be refrozen. Universal precautions for preparation, administration, and handling should be followed to avoid accidental exposure. Health care providers should wear personal protective equipment, and materials that come into contact with talimogene laherparepvec should be disposed of in accordance with local institutional procedures. Individuals who are immunocompromised or pregnant should not prepare or administer this agent. Talimogene laherparepvec is administered by intralesional injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable, or detectable by ultrasound. Treatment should be continued for ≥6 months. As with other immunotherapies, patients may experience an increase in the size of existing lesion(s) or the appearance of new lesions (ie, progression) prior to achieving a response ("pseudo-progression"). As several health care professionals (eg, physicians [dermatologists, surgeons, oncologists, radiologists], pharmacists, nurses) are involved in different stages of the process, there is a need for good interdisciplinary collaboration when using talimogene laherparepvec. Although there are specific requirements for this agent's storage, handling, administration, and disposal, these can be effectively managed in a real-world clinical setting through the implementation of training programs and straightforward standard operating procedures.

Keywords
herpes simplex virus, intralesional injection, melanoma, oncolytic immunotherapy, practical considerations, talimogene laherparepvec
Pubmed
Web of science
Open Access
Yes
Create date
17/09/2017 16:06
Last modification date
20/08/2019 14:59
Usage data